Chimerix CMRX 深 滬
等待開盤 10-23 09:30:00 美东时间
8.54
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 8.54
- 總市值 8.01亿
- 52周最高 8.55
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.75
- 委 比 0.00%
- 總股本 9380.38万
- 歷史最高 58.04
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.75
- 每 手 1
- 風險率 2.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
<p>Clearmind Medicine Inc. has completed enrollment for the first cohort of its Phase I/IIa clinical trial for CMND-100, an oral drug candidate for treating Alcohol Use Disorder (AUD). Six patients were enrolled across sites at Johns Hopkins University School of Medicine and Yale School of Medicine. The trial assesses safety, tolerability, and pharmacokinetics, while exploring preliminary efficacy in reducing alcohol cravings and consumption. CEO...
10-21 11:25
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
CorMedix Inc. announced the completion of its acquisition of Melinta Therapeutics, expanding its portfolio with seven drug products and pipeline opportunities. The deal is expected to generate $325–$350 million in 2025 pro forma revenues and enhance profitability, with potential peak sales for REZZAYO™ prophylaxis exceeding $200 million. Key leadership roles have been finalized, and annual synergies are projected at $35–$45 million. The acquisiti...
09-02 11:30
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m. IST to provide an over...
08-21 04:15
Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Clearmind Medicine Inc. announced the successful initiation of its Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate targeting Alcohol Use Disorder (AUD), at Tel Aviv Sourasky Medical Center (TASMC). This trial, also conducted at leading US and Israeli institutions, evaluates CMND-100's safety, tolerability, and efficacy in reducing alcohol cravings and consumption. CMND-100, based on the molecule MEAI, has shown promise in pre...
07-23 12:55
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. expands its Phase I/IIa clinical trial for CMND-100, a psychedelic-derived drug for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center (TASMC) as a trial site. TASMC joins prestigious institutions like Yale and Johns Hopkins, strengthening the trial's capacity to evaluate CMND-100's safety and efficacy. The trial follows the enrollment of its first patient on June 5. Clearmind aims to address the global...
06-23 11:55
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
06-04 02:37
Chimerix Terminates Loan and Delists from Nasdaq
The latest announcement is out from Chimerix ( ($CMRX) ). On April 21, 2025, Ch...
04-22 04:52
Jazz Pharmaceuticals Completes Acquisition of Chimerix
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewsw...
04-22 04:05
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims
Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing a $145M settlement to resolve certain antitrust claims filed regarding its ...
04-09 23:46
Top 3 Health Care Stocks That May Crash In Q2
As of April 7, 2025, three stocks in the health care sector could be flashing a...
04-07 23:23
